Literature DB >> 17497724

The National Niemann-Pick C1 disease database: report of clinical features and health problems.

William S Garver1, Gordon A Francis, David Jelinek, Glen Shepherd, James Flynn, Graciela Castro, Cate Walsh Vockley, Donald L Coppock, Kathleen M Pettit, Randy A Heidenreich, F John Meaney.   

Abstract

Niemann-Pick type C1 (NPC1) disease is an autosomal recessive disorder characterized clinically by neonatal jaundice, hepatosplenomegaly, vertical gaze palsy, ataxia, dystonia, and progressive neurodegeneration. The present study provides basic clinical and health information from the National Niemann-Pick C1 disease database that was obtained using a clinical questionnaire of 83 questions mailed to families affected by NPC1 disease living in the United States. The study was conducted over a 1-year period, during which time parents/caregivers and physicians completed the clinical questionnaire. Sixty-four percent (87/136) of the questionnaires were returned, with 53% and 47% representing male and female NPC1 patients, respectively. The average age of diagnosis for NPC1 disease was 10.4 years, with one-half of patients being diagnosed before the age of 6.9 years. The average age of death for NPC1 disease was 16.2 years, with one-half of patients dying before the age of 12.5 years. A common clinical symptom reported at birth was neonatal jaundice (52%), followed by enlargement of the spleen (36%) and liver (31%); ascites (19%) and neonatal hypotonia (6%) were much less frequent. With respect to developmental difficulties, the most common findings included clumsiness (87%), learning difficulties (87%), ataxia (83%), dysphagia (80%), and vertical gaze palsy (81%). Together, these findings confirm and extend previous reports investigating the clinical features associated with NPC1 disease. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17497724     DOI: 10.1002/ajmg.a.31735

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  62 in total

1.  Niemann-Pick disease type C: analysis of 7 patients.

Authors:  Hui Xiong; Xin-Hua Bao; Yue-Hua Zhang; You-Ning Xu; Jiong Qin; Hui-Ping Shi; Xi-Ru Wu
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

Review 2.  Niemann-pick disease type C: implications for sedation and anesthesia for diagnostic procedures.

Authors:  Ning Miao; Xiaowei Lu; Naomi P O'Grady; Nicole Yanjanin; Forbes D Porter; Zenaide M N Quezado
Journal:  J Child Neurol       Date:  2012-02-28       Impact factor: 1.987

3.  Npc1 haploinsufficiency promotes weight gain and metabolic features associated with insulin resistance.

Authors:  David Jelinek; Veronica Millward; Amandip Birdi; Theodore P Trouard; Randall A Heidenreich; William S Garver
Journal:  Hum Mol Genet       Date:  2010-10-29       Impact factor: 6.150

4.  Therapeutic potential of cyclodextrins in the treatment of Niemann-Pick type C disease.

Authors:  Benny Liu
Journal:  Clin Lipidol       Date:  2012-06

5.  Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann-Pick C disease.

Authors:  Mathieu Anheim; Ouhaïd Lagha-Boukbiza; Marie-Céline Fleury-Lesaunier; Maria-Paola Valenti-Hirsch; Edouard Hirsch; Hélène Gervais-Bernard; Emmanuel Broussolle; Stéphane Thobois; Marie T Vanier; Philippe Latour; Christine Tranchant
Journal:  J Neurol       Date:  2013-11-01       Impact factor: 4.849

6.  Functional relevance of genes implicated by obesity genome-wide association study signals for human adipocyte biology.

Authors:  F Bernhard; K Landgraf; N Klöting; A Berthold; P Büttner; D Friebe; W Kiess; P Kovacs; M Blüher; A Körner
Journal:  Diabetologia       Date:  2012-11-16       Impact factor: 10.122

7.  TNF-{alpha} plays a role in hepatocyte apoptosis in Niemann-Pick type C liver disease.

Authors:  Victoria M Rimkunas; Mark J Graham; Rosanne M Crooke; Laura Liscum
Journal:  J Lipid Res       Date:  2008-09-24       Impact factor: 5.922

Review 8.  Niemann-Pick disease type C.

Authors:  Marie T Vanier
Journal:  Orphanet J Rare Dis       Date:  2010-06-03       Impact factor: 4.123

9.  Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease.

Authors:  Melanie Vincent; Naomi L Sayre; Mark J Graham; Rosanne M Crooke; David J Shealy; Laura Liscum
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

10.  New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat.

Authors:  James E Wraith; Jackie Imrie
Journal:  Ther Clin Risk Manag       Date:  2009-11-18       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.